본문 바로가기 대메뉴 바로가기

진료과 검색

충북대학교병원 로고
게시물 검색
의료진 찾기

[총 0명이 검색되었습니다.]

혈액종양내과

김홍식 교수

전문분야

간/췌담도암, 비뇨기/부인암, 원발미상암, 육종, 흑색종

진료일정

원모양 외래 삼각형모양 클리닉
테이블 자료 : 진료시간, 오전, 오후, 요일별 가능날짜 정보제공
월 화 수 목 금
오전 진료
오후 진료 진료
비고 -
학회 및 출장등의 이유로 실제 진료스케줄과 차이가 있을 수 있습니다.
진료예약
김홍식 교수

충북대학교병원 X 혈액종양내과

의료진 한마디

학력 및 경력

  • 충북대학교 의과대학 의학사
  • 충북대학교 의과대학 의학석사
  • 충북대학교 의과대학 의학박사
  • 충북대학교병원 인턴
  • 충북대학교병원 내과 전공의
  • 삼성서울병원 혈액종양내과 임상강사
  • 현 충북대학교 의과대학 부교수

학회활동

  • 미국임상암학회 정회원
  • 대한항암요법연구회 정회원
  • 대한종양내과학회 정회원
  • 대한암학회 정회원
  • 대한내과학회 정회원
  • 대한종양내과학회 국제 학술대회 최우수 포스터상 (2024)
  • 대한암학회 제14회 머크 암학술상 (2024)
논문연구실적 - 발표년도, 논문명 정보 제공
발표년도 제목
2025 Targeted Suppression of CEACAM6 via pHLIP-Delivered RNAs in Pancreatic Ductal Adenocarcinoma {2025} 2025 Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries {2025} 2025 Discordance in Claudin 18.2 Expression Between Primary and Metastatic Lesions in Patients With Gastric Cancer {2025} 2025 Differential diagnosis of synchronous double primary squamous cell carcinomas of the esophagus and occult primary oropharynx through HPV testing: A case report {2025} 2025 Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin {2025} 2025 Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis {2025} 2024 Synchronous pancreatic adenocarcinoma andduodenal mucosa‑associated lymphoid tissue lymphoma: Acase report. Medicine {2024} 2024 Clinical Outcomes of Maintenance DurvalumabAfter Definitive Concurrent Chemoradiotherapy in Unresectable Locally AdvancedStage III NSCLC According to EGFR and ALK Status: Korean Cancer Study GroupLU-22-18. JTO Clinical and Research Reports {2024} 2024 Real-World Study of Systemic Treatmentafter First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma inAsia-Pacific Countries. Liver Cancer {2024} 2024 Novel diagnostic biomarkers for pancreaticcancer: assessing methylation status with epigenetic-specific peptide nucleicacid and KRAS mutation in cell-free DNA. Frontiers in Oncology {2024} 2024 Therapeutic Effect of Anti-inflammatoryTripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to AnticancerDrugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. CancerResearch and Treatment {2024} 2024 Efficacy of ferric carboxymaltose ordarbepoetin alfa for chemotherapy-induced anemia in patients withesophagogastric or pancreaticobiliary cancer: a retrospective comparative study.Therapeutic Advances in Medical Oncology {2024} 2024 Value of glucose transport protein 1 expressionin detecting lymph node metastasis in patients with colorectal cancer. WorldJournal of Clinical Cases {2024} 2023 Pembrolizumab-induced psoriatic arthritistreated with disease-modifying anti-rheumatic drugs in a patient with gastriccancer: A case report. World Journal of Clinical Cases {2023} 2023 Neoadjuvant Nivolumab plus Gemcitabine/CisplatinChemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder. CancerResearch and Treatment {2023} 2023 EGFR Mutation-Positive Unresectable StageIII Non-Squamous Lung Cancer Is Associated with a High Incidence of BrainMetastasis. Cancer Research and Treatment {2023} 2022 The new diagnostic criteria formyelodysplasia-related acute myeloid leukemia is useful for predicting clinicaloutcome: comparison of the 4th and 5th World Health Organizationclassifications. Annals of Hematology {2022} 2022 Long-Term Breast Cancer Outcomes ofPregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort. Cancers {2022} 2022 Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. Therapeutic Advances in Gastroenterology {2022} 2022 A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Frontiers in Oncology {2022} 2022 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. Cancer research and treatment {2022} 2022 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clinical oncology {2022} 2022 HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology {2022} 2022 Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer. {2022} 2022 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Cancer research and treatment {2022} 2022 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. Cancer research and treatment {2022} 2021 The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Frontiers in Oncology {2021} 2021 Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technology in Cancer Research & Treatment {2021} 2021 A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer. BMC Cancer {2021} 2021 Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers {2021} 2021 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of cancer research and clinical oncology {2021} 2021 When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. Journal of Cancer {2021} 2021 Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. Translational lung cancer research {2021} 2020 Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. Scientific reports {2020} 2019 Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions. BMC cancer {2019} 2018 Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report. World Journal of Gastroenterology {2018}
번호, 진료언론사, 보도명, 보도일자 정보제공
번호 언론사 보도명 보도일자